Evidence map›Paper›PMID 37568825›Full record

ArticleCancers2023

Influence of De Novo Malignancies on Long-Term Survival after Lung Transplantation.

Eloisa Ruiz, Paula Moreno, Francisco Javier Gonzalez, Alba Maria Fernandez, Benito Cantador, Juan Luis Parraga, Angel Salvatierra, Antonio Alvarez

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Public Health Risks of PFAS-Related Immunotoxicity Are Real.Current environmental health reports · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Eloisa RuizDepartment of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofia, 14004 Cordoba, Spain.
Paula MorenoDepartment of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofia, 14004 Cordoba, Spain.
Francisco Javier GonzalezDepartment of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofia, 14004 Cordoba, Spain.
Alba Maria FernandezDepartment of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofia, 14004 Cordoba, Spain.ORCID 0000-0001-6426-5460
Benito CantadorDepartment of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofia, 14004 Cordoba, Spain.
Juan Luis ParragaDepartment of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofia, 14004 Cordoba, Spain.
Angel SalvatierraDepartment of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofia, 14004 Cordoba, Spain.
Antonio AlvarezDepartment of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofia, 14004 Cordoba, Spain.ORCID 0000-0003-1531-9543
Hospital Universitario Reina Sofía · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Malignancies are an important cause of mortality after solid organ transplantation. The purpose of this study was to analyze the incidence of malignancies in patients receiving lung transplants (LT) and their influence on patients' survival. (2) Methods: Review of consecutive LT from 1994 to 2021. Patients with and without malignancies were compared by univariable and multivariable analyses. Survival was compared with Kaplan-Meier and Cox regression analysis. (3) Results: There were 731 LT malignancies developed in 91 patients (12.4%) with related mortality of 47% (

Indexed as

lung cancerlung transplantationmalignanciesoutcomessurvival

Identifiers

PMID37568825
PMCPMC10417357
OpenAlexW4385654777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.